Analysis of the relationship between PD-1 levels and tumor stages in patients with prostate cancer
Objective To analyze the relationship between programmed death 1(PD-1)ex-pression in prostate cancer(PCa)patients and tumor stage.Methods Postoperative tissue specimens of 150 PCa patients admitted to our hospital from January 2018 to January 2021 were selected as the study object(PCa group),and postoperative tissue specimens of 130 hospitalized patients with benign prostate hyperplasia(BPH)undergoing surgical treatment during the same period were selected as the BPH group.PD-1 expression was detected by immunohistochemistry and ELISA.PCa cells were divid-ed into control group,50 μg/L group and 100 μg/L group.The migration morphology of PC3 cells was detected by scratch test and Transwell laboratory test,respectively.Results PD-1 expression level in PCa group was higher than that in BPH group,and the difference was statistically significant(P=0.001).The expression level of PD-1 was(13.60±6.31)pg/mL in patients with stage Ⅰ PCa,(16.51±4.88)pg/mL in patients with stage Ⅱ PCa,(21.68±5.13)pg/mL in patients with stageⅢ PCa,and(29.50±4.78)pg/mL in patients with stage Ⅳ PCa.The expression level of PD-1 in-creased gradually with the progression of tumor stage(all P＜0.05).The expression level of PD-1 in patients with Gleason score 7-10 in PCa group was higher than those with Gleason score 1-6,and the difference was statistically significant(P＜0.001).The number of PC3 cells migrated with the extension of culture time,the degree of cell healing was stronger(P＜0.05).The results of Transwell laboratory experiment showed that the migration distance of 50 μg/L group and 100 μg/L group was longer than that of control group(all P＜0.05).Conclusions The clinical value of PD-1 as a biomarker for PC progression and prognosis assessment needs further study.PD-1 targeting may be a potential target for the treatment of human prostate cancer.
Prostatic NeoplasmsProgrammed Death Receptor 1Neoplasm Staging
NETL
NSTL
万方数据
